Substance for restoring normal co-expression and interaction between the LOX and NRAGE proteins
US9308161B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 25, 2012 |
| Grant date | Apr 12, 2016 |
| Priority date | — |
| Expiry date | May 10, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2800/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosed substance restores normal co-expression and interaction between the LOX and NRAGE proteins. Particularly, an effective amount of the substance that modulates the expression and/or activity of LOX of SEQ ID NO: 1 and/or that modulates the expression and/or activity of NRAGE of SEQ ID NO: 2, may be used for the manufacture of a composition for modulating the interaction between the LOX and NRAGE proteins to regulate the balance between the cellular phenomena of proliferation, differentiation and apoptosis, particularly in cases where the balance between these phenomena is disturbed, and especially in cases where the interaction between LOX and NRAGE is absent or altered. The invention makes it possible especially to treat and/or prevent skin ageing, lichen planus, graft-versus-host reaction (GVH), eczema, psoriasis and a cancer, particularly an epithelial cancer and more particularly a cutaneous epithelial cancer of basocellular or spinocellular type.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.